Literature DB >> 20102753

Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.

Akos Végvári1, Melinda Rezeli, Charlotte Welinder, Johan Malm, Hans Lilja, György Marko-Varga, Thomas Laurell.   

Abstract

Measurements of the prostate-specific antigen (PSA) levels in blood are widely used as diagnostic, predictive and prognostic marker of prostate disease. The selective detection of molecular forms of PSA can contribute clinically to meaningful enhancements of the conventional PSA-test. As it is plausible that an in-depth search for structural variants of PSA gene products may increase our ability to discriminate distinct patho-biological basis and stages of prostate diseases, we have developed a multi-step protocol comprising gel-based methods followed by mass spectrometric identification. Our current aim was to provide a comprehensive identification of PSA variants occurring in seminal fluid. We provide a proof-of-principle for this multiple step analytical approach to identify multiple PSA variants from complex biological samples that revealed distinct molecular characteristics. In addition, sequence-annotated protein bands in SDS-PAGE gels were compared to those detected by Western blots, and by monitoring the enzymatic activity in zymogram gels, using gelatin as a substrate. The high accuracy annotations were obtained by fast turnaround MALDI-Orbitrap analysis from excised and digested gel bands. Multiple PSA forms were identified utilizing a combination of MASCOT and SEQUEST search engines. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102753      PMCID: PMC2856840          DOI: 10.1016/j.jprot.2010.01.008

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  24 in total

1.  Molecular cloning of human prostate specific antigen cDNA.

Authors:  A Lundwall; H Lilja
Journal:  FEBS Lett       Date:  1987-04-20       Impact factor: 4.124

2.  Human prostate-specific antigen: structural and functional similarity with serine proteases.

Authors:  K W Watt; P J Lee; T M'Timkulu; W P Chan; R Loor
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

3.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

Authors:  H Lilja
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

4.  Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.

Authors:  P Nurmikko; K Pettersson; T Piironen; J Hugosson; H Lilja
Journal:  Clin Chem       Date:  2001-08       Impact factor: 8.327

5.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin.

Authors:  H Lilja; A Christensson; U Dahlén; M T Matikainen; O Nilsson; K Pettersson; T Lövgren
Journal:  Clin Chem       Date:  1991-09       Impact factor: 8.327

6.  Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia.

Authors:  S D Mikolajczyk; L S Millar; K M Marker; T J Wang; H G Rittenhouse; L S Marks; K M Slawin
Journal:  Prostate       Date:  2000-11-01       Impact factor: 4.104

7.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.

Authors:  A Christensson; C B Laurell; H Lilja
Journal:  Eur J Biochem       Date:  1990-12-27

8.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

9.  Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate.

Authors:  Elga Pezzato; Luigi Sartor; Isabella Dell'Aica; Ruggero Dittadi; Massimo Gion; Claudio Belluco; Mario Lise; Spiridione Garbisa
Journal:  Int J Cancer       Date:  2004-12-10       Impact factor: 7.396

10.  Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen.

Authors:  H Lilja; J Oldbring; G Rannevik; C B Laurell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

View more
  8 in total

1.  Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.

Authors:  Akos Végvári; Melinda Rezeli; Jari Häkkinen; Carina Sihlbom; Elisabet Carlsohn; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  J Proteomics       Date:  2011-06-23       Impact factor: 4.044

2.  MALDI-target integrated platform for affinity-captured protein digestion.

Authors:  Asilah Ahmad-Tajudin; Belinda Adler; Simon Ekström; György Marko-Varga; Johan Malm; Hans Lilja; Thomas Laurell
Journal:  Anal Chim Acta       Date:  2013-09-11       Impact factor: 6.558

3.  Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.

Authors:  Ákos Végvári; Melinda Rezeli; Carina Sihlbom; Jari Häkkinen; Elisabet Carlsohn; Johan Malm; Hans Lilja; Thomas Laurell; György Marko-Varga
Journal:  Clin Biochem       Date:  2011-12-16       Impact factor: 3.281

4.  Biobank resources for future patient care: developments, principles and concepts.

Authors:  Akos Végvári; Charlotte Welinder; Henrik Lindberg; Thomas E Fehniger; György Marko-Varga
Journal:  J Clin Bioinforma       Date:  2011-09-16

5.  Expanding the mouse embryonic stem cell proteome: combining three proteomic approaches.

Authors:  Rebekah L Gundry; Irina Tchernyshyov; Shijun Sheng; Yelena Tarasova; Kimberly Raginski; Kenneth R Boheler; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2010-07       Impact factor: 3.984

6.  Evaluation of molecular species of prostate-specific antigen complexed with immunoglobulin M in prostate cancer and benign prostatic hyperplasia.

Authors:  Sanja Goč; Miroslava Janković
Journal:  Dis Markers       Date:  2013-12-03       Impact factor: 3.434

7.  Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012.

Authors:  Nancy Leymarie; Paula J Griffin; Karen Jonscher; Daniel Kolarich; Ron Orlando; Mark McComb; Joseph Zaia; Jennifer Aguilan; William R Alley; Friederich Altmann; Lauren E Ball; Lipika Basumallick; Carthene R Bazemore-Walker; Henning Behnken; Michael A Blank; Kristy J Brown; Svenja-Catharina Bunz; Christopher W Cairo; John F Cipollo; Rambod Daneshfar; Heather Desaire; Richard R Drake; Eden P Go; Radoslav Goldman; Clemens Gruber; Adnan Halim; Yetrib Hathout; Paul J Hensbergen; David M Horn; Deanna Hurum; Wolfgang Jabs; Göran Larson; Mellisa Ly; Benjamin F Mann; Kristina Marx; Yehia Mechref; Bernd Meyer; Uwe Möginger; Christian Neusüβ; Jonas Nilsson; Milos V Novotny; Julius O Nyalwidhe; Nicolle H Packer; Petr Pompach; Bela Reiz; Anja Resemann; Jeffrey S Rohrer; Alexandra Ruthenbeck; Miloslav Sanda; Jan Mirco Schulz; Ulrike Schweiger-Hufnagel; Carina Sihlbom; Ehwang Song; Gregory O Staples; Detlev Suckau; Haixu Tang; Morten Thaysen-Andersen; Rosa I Viner; Yanming An; Leena Valmu; Yoshinao Wada; Megan Watson; Markus Windwarder; Randy Whittal; Manfred Wuhrer; Yiying Zhu; Chunxia Zou
Journal:  Mol Cell Proteomics       Date:  2013-06-13       Impact factor: 5.911

8.  Moving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels.

Authors:  Melinda Rezeli; Akos Végvári; Thomas E Fehniger; Thomas Laurell; György Marko-Varga
Journal:  J Clin Bioinforma       Date:  2011-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.